C
Catalyst Pharmaceuticals, Inc. (CPRX)
NCM – Real Time Price. Currency in USD
31.14
-0.01 (-0.03%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
31.14
-0.01 (-0.03%)
At close: May 12, 2026, 4:00 PM EDT
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Name | Position |
|---|---|
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO |
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman |
| Mr. Paul Friel | Executive Vice President of Corporate Operations |
| Mr. Richard John Daly M.B.A. | President, CEO & Director |
| Ms. Mary Coleman | VP & Head of Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | DEFA14A | d141405ddefa14a.htm |
| 2026-05-07 | 8-K | d90722d8k.htm |
| 2026-04-30 | 10-K/A | d134396d10ka.htm |
| 2026-03-19 | 8-K/A | d25173d8ka.htm |
| 2026-03-18 | 8-K | d111324d8k.htm |
| 2026-02-25 | 8-K | d108222d8k.htm |
| 2026-02-25 | 10-K | cprx-20251231.htm |
| 2026-01-12 | 8-K | d62132d8k.htm |
| 2025-11-05 | 10-Q | cprx-20250930.htm |
| 2025-10-01 | 8-K | d118298d8k.htm |